Amanda Bolgioni-Smith
Boston University Medical School
We demonstrated that inactivating a specific molecular pathway (the “Hippo” pathway) in cancer cells makes them less sensitive to the chemotherapy drug Taxol; in the future this knowledge could be used to develop a chemotherapeutic plan for cells inherently resistant to Taxol in breast, lung and ovarian cancers.